Deerfield Mgmt Exits Catalyst Pharma (CPRX) Position

TL;DR

**Deerfield Mgmt dumped all its CPRX shares, big institutional exit!**

AI Summary

Deerfield Mgmt, L.P. and its affiliates, including Deerfield Management Company, L.P. and Deerfield Partners, L.P., have filed an amended SC 13G/A for Catalyst Pharmaceuticals, Inc. (CPRX) as of December 31, 2023. This filing indicates a change in their beneficial ownership, specifically that they now beneficially own 0 shares of Catalyst Pharmaceuticals' common stock, down from a previously reported stake. This matters to investors because it signals a complete exit from their position in CPRX by a significant institutional investor, which could be interpreted negatively.

Why It Matters

This filing shows a major institutional investor, Deerfield Mgmt, has sold all its shares in Catalyst Pharmaceuticals, which could signal a lack of confidence in the company's future prospects.

Risk Assessment

Risk Level: medium — The complete divestment by a large institutional investor like Deerfield Mgmt could indicate underlying concerns or a shift in investment strategy, potentially impacting investor sentiment.

Analyst Insight

Investors should investigate the reasons behind Deerfield Mgmt's complete divestment from Catalyst Pharmaceuticals and consider if this signals a broader negative outlook before making investment decisions.

Key Numbers

• 0 — shares beneficially owned (Deerfield Mgmt, L.P. and its affiliates now own zero shares of Catalyst Pharmaceuticals, Inc.)

Key Players & Entities

• Deerfield Mgmt, L.P. (company) — reporting person and institutional investor
• Catalyst Pharmaceuticals, Inc. (company) — the issuer of the securities
• Deerfield Management Company, L.P. (company) — group member of the reporting entity
• Deerfield Partners, L.P. (company) — group member of the reporting entity
• James E Flynn (person) — filed by

Forward-Looking Statements

• Catalyst Pharmaceuticals' stock price may experience downward pressure due to the institutional exit. (Catalyst Pharmaceuticals, Inc.) — medium confidence, target: short-term

FAQ

Filing Documents

• e619253_sc13ga-cp.htm (SC 13G/A) — 99KB
• 0001193805-24-000191.txt ( ) — 101KB

(a)

Item 1(a). Name of Issuer: Catalyst Pharmaceuticals, Inc.

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 355 Alhambra Circle, Suite 801 Coral Gables, Florida, 33134

(a)

Item 2(a). Name of Person Filing: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.

(b)

Item 2(b). Address of Principal Business Office, or if None, Residence: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

(c)

Item 2(c). Citizenship: Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships; James E. Flynn – United States citizen

(d)

Item 2(d). Title of Class of Securities: Common Stock

(e)

Item 2(e). CUSIP Number: 14888U101 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) Bank as defined in Section 3(a)(6) of the Exchange Act. (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) Investment company registered under Section 8 of the Investment Company Act. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); CUSIP No. 14888U101 13G Page 7 of 9 (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________ Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned**: Deerfield Mgmt, L.P. - 8,888,901 shares Deerfield Management Company, L.P. - 8,888,901 shares Deerfield Partners, L.P. - 8,888,901 shares James E. Flynn – 8,888,901 shares (b) Percent of class**: Deerfield Mgmt, L.P. – 8.34% Deerfield Management Company, L.P. – 8.34% Deerfield Partners, L.P. – 8.34% James E. Flynn – 8.34% (c) Number of shares as to which such person has**: (i) Sole power to vote or to direct the vote: All Reporting Persons - 0 (ii) Shared power to vote or to di

View Full Filing

View this SC 13G/A filing on SEC EDGAR